<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="LL-37 – Reduced morbidity and mortality to similar levels as" exact="zanamivir" post="in mice. – Mouse-adapted laboratory IAV (H1N1) (21) Influenza"/>
 <result pre="morbidity and mortality to similar levels as the neuraminidase inhibitor" exact="zanamivir" post="that is used for the treatment of human influenza"/>
 <result pre="H1N1 IAV; interestingly, this inhibitor significantly out-performed the clinically recommended" exact="oseltamivir" post="in these studies (26). Another central regulator of immune"/>
 <result pre="virion uncoating (28). Although in vivo inhibition of GRK2 using" exact="paroxetine" post="led to a significant reduction in upper respiratory tract"/>
 <result pre="IAV infected mice (31). Prophylactic treatment of H1N1-infected mice with" exact="pioglitazone" post="(PPARγ agonist) resulted in increased survival (32). Combined activation"/>
 <result pre="Clin Invest. (2013) 123:206–14. 10.1172/JCI6166723202729 31.BuddAAllevaLAlsharifiMKoskinenASmytheVMullbacherAet al.. Increased survival after" exact="gemfibrozil" post="treatment of severe mouse influenza. Antimicrob Agents Chemother. (2007)"/>
 <result pre="Res. (2011) 92:195–203. 10.1016/j.antiviral.2011.08.00221854809 61.HaasbachEHartmayerCPlanzO. Combination of MEK inhibitors and" exact="oseltamivir" post="leads to synergistic antiviral effects after influenza A virus"/>
</results>
